NetworkNewsBreaks – Genprex Inc. (NASDAQ: GNPX)
Post# of 231
(Total Views: 270)
Posted On: 04/20/2021 4:12:50 PM
NetworkNewsBreaks – Genprex Inc. (NASDAQ: GNPX) Receives License of Year Award for Advances Made with Gene Therapy Program in Diabetes
Genprex (NASDAQ: GNPX), a clinical-stage gene therapy company developing potentially life-changing technologies for patients with cancer and diabetes, was named the recipient of the first-ever License of the Year award presented from the University of Pittsburgh Innovation Institute (“UPII”). The award honors advances made with GNPX’s license from University of Pittsburgh toward progressing the development of its gene therapy for diabetes. GNPX has been involved in groundbreaking, potentially curative gene therapy shown to transform alpha cells in the pancreas into functional beta-like cells. The therapy, which involves the diabetes gene therapy candidate GPX-002, is potentially applicable to both type 1 and type 2 diabetes. Genprex signed an exclusive license agreement with the University of Pittsburgh in February 2020. The agreement involves an innovative gene therapy technology developed by lead researcher, George Gittes, MD at the Rangos Research Center at the University of Pittsburgh Medical Center (“UPMC”) Children’s Hospital. “We thank the UPII for acknowledging the breakthrough work of Dr. George Gittes and his team at the Rangos Research Center at UPMC Children’s Hospital of Pittsburgh, whose efforts have produced this highly innovative therapeutic approach to treating diabetes that could replace the need for insulin replacement therapy and ultimately lead to a cure of this devastating illness afflicting tens of millions of people around the world,” said Genprex president and CEO Rodney Varner in the press release. “We are honored to receive this recognition, considering the great number of cutting-edge technologies coming out of this distinguished university and research center. We thank UPII for bestowing this honor on our gene therapy license with Dr. Gittes and the Rangos Research Center and applaud them for the groundbreaking gene therapy research being conducted at this esteemed institution.”
Please see full disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer
Genprex (NASDAQ: GNPX), a clinical-stage gene therapy company developing potentially life-changing technologies for patients with cancer and diabetes, was named the recipient of the first-ever License of the Year award presented from the University of Pittsburgh Innovation Institute (“UPII”). The award honors advances made with GNPX’s license from University of Pittsburgh toward progressing the development of its gene therapy for diabetes. GNPX has been involved in groundbreaking, potentially curative gene therapy shown to transform alpha cells in the pancreas into functional beta-like cells. The therapy, which involves the diabetes gene therapy candidate GPX-002, is potentially applicable to both type 1 and type 2 diabetes. Genprex signed an exclusive license agreement with the University of Pittsburgh in February 2020. The agreement involves an innovative gene therapy technology developed by lead researcher, George Gittes, MD at the Rangos Research Center at the University of Pittsburgh Medical Center (“UPMC”) Children’s Hospital. “We thank the UPII for acknowledging the breakthrough work of Dr. George Gittes and his team at the Rangos Research Center at UPMC Children’s Hospital of Pittsburgh, whose efforts have produced this highly innovative therapeutic approach to treating diabetes that could replace the need for insulin replacement therapy and ultimately lead to a cure of this devastating illness afflicting tens of millions of people around the world,” said Genprex president and CEO Rodney Varner in the press release. “We are honored to receive this recognition, considering the great number of cutting-edge technologies coming out of this distinguished university and research center. We thank UPII for bestowing this honor on our gene therapy license with Dr. Gittes and the Rangos Research Center and applaud them for the groundbreaking gene therapy research being conducted at this esteemed institution.”
Please see full disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer
(0)
(0)